SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Increasing average concentrations of sotatercept improved 6-minute walk distance, pulmonary vascular resistance, and levels of NT-proBNP.

INR:0541. thimble casino game Keytruda beats Adcetris in a head-to-head Phase III study of classic Hodgkin lymphoma! Phase I clinical trial application for in ...

INR:5962. slots mega apk New breakthrough in liquid biopsy technology! AI blood test is expected to screen for early lung cancer Phase I clinical trial application ...